The company employs a semi-virtual model with a hub based in Cambridge, UK. The team is staffed with experienced drug discovery professionals to direct an out-sourced development program. This model ensures maximum capital efficiency without sacrificing quality.
The science behind Morphogen-IX is based on years of research in the British Heart Foundation funded laboratory of Professor Nick Morrell and colleagues at the University of Cambridge.
Our goal is to transform the lives of patients by targeting the disease-causing pathway identified from human genetic studies in patients with pulmonary arterial hypertension
Morphogen-IX Ltd, a biotechnology company focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), today announced the nomination of its clinical development candidate and initiation of formal preclinical development. The agent, MGX292, is a protein-engineered variant of BMP9 that has proven highly efficacious and safe in extensive preclinical studies.